Since PARP inhibitors represent another promising chemotherapeutic in the treatment of patients with ovarian cancer, we also assessed whether SFXN4 knockdown would sensitize ovarian cancer cells to the PARP inhibitor niraparib. Here, SFXN4 is linked to ovarian cancer.